Skip to main content

Table 2 Protein expression of inflammatory factors in patients on day 1 and day 7

From: Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro

inflammatory meditors (pg/ml)

Patient A

Patient B

Day1

Day7

Day1

Day7

PDGF-AA/BB

417.63

2018.76

2390.86

1662.27

Eotaxin

19.05

83.34

41.54

22.47

MCP-1

15.3

345.62

45.36

28.24

MIP-1α

0.75

85.26

7.02

4.38

MIP-1β

52.65

343.41

250.35

227.16

GRO

103.05

716.22

467.43

536.83

CCL-5

4264.44

33,165.25

24,171.29

17,321.52

MCP-3

0.31

55.25

0.86

1.32

IL-6

1.32

53.78

7.28

1.45

IP-10

113.95

468.62

478.84

311.53

IL-1α

55.53

55.53

308.72

143.43